Genomic Health, Inc. (NASDAQ:GHDX) insider Laura Leber sold 21,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $33.29, for a total transaction of $699,090.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Genomic Health, Inc. (NASDAQ:GHDX) opened at $36.13 on Thursday. Genomic Health, Inc. has a fifty-two week low of $26.37 and a fifty-two week high of $37.50.

Several hedge funds have recently bought and sold shares of GHDX. Vanguard Group Inc. boosted its holdings in shares of Genomic Health by 6.8% in the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock valued at $54,379,000 after acquiring an additional 106,452 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Genomic Health by 10.9% during the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after purchasing an additional 80,100 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Genomic Health by 26.1% during the second quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock worth $12,070,000 after purchasing an additional 76,758 shares during the period. Citadel Advisors LLC lifted its holdings in shares of Genomic Health by 269.5% during the third quarter. Citadel Advisors LLC now owns 93,803 shares of the medical research company’s stock worth $3,010,000 after purchasing an additional 68,418 shares during the period. Finally, Cowen Prime Services LLC lifted its holdings in shares of Genomic Health by 324.1% during the second quarter. Cowen Prime Services LLC now owns 88,635 shares of the medical research company’s stock worth $2,885,000 after purchasing an additional 67,735 shares during the period. 89.61% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have commented on GHDX shares. Zacks Investment Research upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. Cowen reiterated a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a research note on Friday, September 1st. Canaccord Genuity reissued a “buy” rating and issued a $39.00 price objective on shares of Genomic Health in a report on Wednesday, November 15th. Jefferies Group reissued a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a report on Thursday, September 14th. Finally, ValuEngine raised Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the stock. Genomic Health presently has a consensus rating of “Hold” and an average price target of $31.57.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Genomic Health, Inc. (GHDX) Insider Sells $699,090.00 in Stock” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/insider-selling-genomic-health-inc-ghdx-insider-sells-699090-00-in-stock/1775891.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.